Page 821 - Cardiac Nursing

6
2
/
0
009
2:0
2:0
009
1
98.
98.
3-7
3-7
qx
0
0
d
3
M
M
A
A
Pa
Apt
ara
e 7
97
A
A
7 A
A
A
A
A
A
A
K34
K34
34_
0-c
LWB
LWB K34 0-c 34_ p78 3-7 98. qx d 3 0 / 0 6 / / 2 009 1 2:0 7 A M Pa g g e 7 97 Apt ara
LWBK340-c34_p78p783-798.qxd 30/06/2009 12:07 AM Page 797 Aptara
p78
C HAPTER 3 4 / Smoking Cessation and Relapse Prevention 797
49. Stanislaw, A. E., & Wewers, M. E. (1994). A smoking cessation intervention 76. Oncken, C., Gonzales, D., Nides, M., et al. (2006). Efficacy and safety of
7
7
with hospitalized surgical cancer patients: A pilot study. Cancer Nursing, 17, the novel selective nicotinic acetylcholine receptor partial agonist, vareni-
6
81–86. cline, for smoking cessation. Archives of Internal Medicine, 166, 1571–1577.
6
50. Miller, N. H., Smith, P. M., DeBusk, R. F., et al. (1997). Smoking ces- 77. Freedman, R. (2007). Exacerbation of schizophrenia by varenicline.
4
4
sation in hospitalized patients. Results of a randomized trial. Archives of American Journal of Psychiatry, 164, 1269.
Internal Medicine, 157, 409–415. 78. Kohen, I., & Kremen, N. (2007). Varenicline-induced manic episode in
7
7
51. Glasgow, R. E., Stevens, V. J., Vogt, T. M., et al. (1991). Changes in smok- a patient with bipolar disorder. American Journal of Psychiatry, 164,
4
4
ing associated with hospitalization: Quit rates, predictive variables, and in- 1269–1270.
6
tervention implications. American Journal of Health Promotion, 6, 24–29. 79. GlaxoSmithKline. Zyban prescribing information. Retrieved from http://
6
52. Ockene, J. K., Hosmer, D., Rippe, J., et al. (1985). Factors affecting cig- us.gsk.com/products/assets/us_zyban.pdf
arette smoking status in patients with ischemic heart disease. Journal of 80. Hays, J. T., & Ebbert, J. O. (2003). Bupropion for the treatment of to-
8
Chronic Diseases, 38, 985–994. bacco dependence: Guidelines for balancing risks and benefits. CNS
7
7
53. Hutchinson, K. M., & Froelicher, E. A. (2003). Populations at risk for Drugs, 17, 71–83.
9
9
tobacco-related diseases. Seminars in Oncology Nursing, 19, 276–283. 81. Smith, S. S., Jorenby, D. E., Leischow, S. J., et al. (2003). Targeting
54. Krumholz, H. M., Cohen, B. J., Tsevat, J., et al. (1993). Cost-effectiveness smokers at increased risk for relapse: Treating women and those with a
5
of a smoking cessation program after myocardial infarction. Journal of the history of depression. Nicotine & Tobacco Research, 5, 99–109.
5
2
American College of Cardiology, 22, 1697–1702. 82. Aubin, H. J. (2002). Tolerability and safety of sustained-release bupropion
2
55. Fiore, M. C., Novotny, T. E., Pierce, J. P., et al. (1990). Methods used to in the management of smoking cessation. Drugs, 62(Suppl. 2), 45–52.
quit smoking in the United States. Do cessation programs help? Journal 83. Haustein, K. O. (2003). Bupropion: Pharmacological and clinical profile
of the American Medical Association, 263, 2760–2765. in smoking cessation. International Journal of Clinical Pharmacology and
56. Emmons, K. M., & Goldstein, M. G. (1992). Smokers who are hospi- Therapeutics, 41, 56–66.
talized: A window of opportunity for cessation interventions. Preventive 84. Holm, K. J., & Spencer, C. M. (2000). Bupropion: A review of its use in
9
9
Medicine, 21, 262–269. the management of smoking cessation. Drugs, 59, 1007–1024.
®
57. Sohn, M., Stotts, N. A., Benowitz, N., et al. (2007). Beliefs about health, 85. Bupropion (Zyban ) for smoking cessation. (1997). Medical Letters on
9
smoking, and future smoking cessation among South Korean men hos- Drugs and Therapeutics, 39, 77–78.
9
6
6
pitalized for cardiovascular disease. Heart & Lung, 36, 339–347. 86. Durcan, M. J., Deener, G., White, J., et al. (2002). The effect of bupro-
58. Sohn, M., Benowitz, N., Stotts, N., et al. (2008). Smoking behavior in pion sustained-release on cigarette craving after smoking cessation. Clin-
men hospitalized with cardiovascular disease in Korea: A cross-sectional ical Therapeutics, 24, 540–551.
4
4
descriptive study. Heart & Lung, 37, 366–379. 87. Hays, J. T., Hurt, R. D., Rigotti, N. A., et al. (2001). Sustained-release
7
7
59. Pechacek, T. F. (1984). Modification of smoking behavior. In Smoking bupropion for pharmacologic relapse prevention after smoking cessation.
5
and health: A report of the Surgeon General. Washington, DC: Govern- A randomized, controlled trial. Annals of Internal Medicine, 135, 423–433.
5
l
l
ment Printing Office. 88. Benowitz, N. L. (1988). Drug therapy. Pharmacologic aspects of ciga-
60. U.S. Department of Health and Human Services. (1996). Treating to- rette smoking and nicotine addition. New England Journal of Medicine,
bacco use and dependence: Clinical practice guideline. Washington, DC: 319, 1318–1330.
9
9
Government Printing Office. 89. Hurt, R. D., Dale, L. C., Croghan, G. A., et al. (1998). Nicotine nasal
61. U.S. Department of Health and Human Services. (2000). Treating to- spray for smoking cessation: Pattern of use, side effects, relief of withdrawal
bacco use and dependence: Clinical practice guideline. Washington, DC: symptoms, and cotinine levels. Mayo Clinic Proceedings, 73, 118–125.
Government Printing Office. 90. Schneider, N. G., Lunell, E., Olmstead, R. E., et al. (1996). Clinical
62. U.S. Department of Health and Human Services. (2008). Treating to- pharmacokinetics of nasal nicotine delivery. A review and comparison to
bacco use and dependence: Clinical practice guideline, 2008 update. Wash- other nicotine systems. Clinical Pharmacokinetics, 31, 65–80.
e
ington, DC: Government Printing Office. 91. West, R., Hajek, P., Nilsson, F., et al. (2001). Individual differences in
63. U.S. Department of Health and Human Services. (2008). Helping smok- preferences for and responses to four nicotine replacement products. Psy-
ers quit: A guide for clinicians. Washington, DC: Government Printing Of- chopharmacology (Berl), 153, 225–230.
fice. 92. Emmons, K. M., Goldstein, M. G., Roberts, M., et al. (2000). The use
64. Sohn, M., Hartley, C., Froelicher, E. S., et al. (2003). Tobacco use and of nicotine replacement therapy during hospitalization. Annals of Behav-
9
dependence. Seminars in Oncology Nursing, 19, 250–260. ioral Medicine, 22, 325–329.
2
2
9
65. American Heart Association. (2002). An active partnership for the health 93. Yerger, V. B., Wertz, M., McGruder, C., et al. (2008). Nicotine replace-
of your heart. Dallas, TX: Author. ment therapy: perceptions of African-American smokers seeking to quit.
t
t
66. U.S. Department of Health and Human Services. (2003). Pathways to Journal of the National Medical Association, 100, 230–236.
0
0
freedom: Winning the fight against tobacco. Atlanta, GA: Centers for Dis- 94. Cummings, S. R., Hansen, B., Richard, R. J., et al. (1988). Internists and
0
ease Control and Prevention. nicotine gum. JAMA, 260, 1565–1569.
0
67. Marlatt, A. G. (1982). Relapse prevention: A self-control program for the 95. Killen, J. D., Fortmann, S. P., Newman, B., et al. (1990). Evaluation of
treatment of addictive behaviors. In R. B. Stuart (Ed.), Adherence, com- a treatment approach combining nicotine gum with self-guided behav-
pliance and generalization in behavioral medicine (pp. 329–378). New ioral treatments for smoking relapse prevention. Journal of Consulting
York: Brunnel/Mazel. and Clinical Psychology, 58, 85–92.
8
68. Ockene, J. K., Emmons, K. M., Mermelstein, R. J., et al. (2000). Relapse 96. Henningfield, J. E., Radzius, A., Cooper, T. M., et al. (1990). Drinking
9
9
and maintenance issues for smoking cessation. Health Psychology, 19, 17–31. coffee and carbonated beverages blocks absorption of nicotine from nico-
69. Condiotte, M. M., & Lichtenstein, E. (1981). Self-efficacy and relapse in tine polacrilex gum. JAMA, 264, 1560–1564.
4
4
smoking cessation programs. Journal of Consulting and Clinical Psychology, 97. Hajek, P., Jackson, P., & Belcher, M. (1988). Long-term use of nicotine
9
9
49, 648–658. chewing gum. Occurrence, determinants, and effect on weight gain.
0
0
70. Gwaltney, C. J., Shiffman, S., Norman, G. J., et al. (2001). Does smok- JAMA, 260, 1593–1596.
ing abstinence self-efficacy vary across situations? Identifying context- 98. Agency for Healthcare Policy and Research: U.S. Department of Health and
specificity within the Relapse Situation Efficacy Questionnaire. Journal Human Services. (1996). Clinical practice guideline: Smoking cessation (Pub-
9
of Consulting and Clinical Psychology, 69, 516–527. lication No. 96-0692). Washington, DC: Government Printing Office.
9
71. Tsoh, J. Y., McClure, J. B., Skaar, K. L., et al. (1997). Smoking cessation. 2: 99. Marion Merrell Dow, Inc. (1991). Nicoderm (nicotine transdermal system)
Components of effective intervention. Behavioral Medicine, 23, 15–27. prescribing information. Kansas City, MO: Author.
72. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., et al. (1991). The 100. Lederle Laboratories. (1992). PROSTEP (nicotine transdermal system)
Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom prescribing information. Wayne, NJ: Author.
6
6
Tolerance Questionnaire. British Journal of Addiction, 86, 1119–1127. 101. Ciba-Geigy Corporation. (1992). Habitrol (nicotine transdermal thera-
73. Fagerström, K. (2003). Time to first cigarette; the best single indicator of peutic system) prescribing information. Edison, NJ: Author.
9
9
tobacco dependence? Monaldi Archives for Chest Disease, 59, 91–94. 102. Parke-Davis. (1992). Nicotrol (nicotine transdermal system) prescribing in-
74. Taylor, C. B., Houston-Miller, N., Haskell, W. L., et al. (1988). Smok- formation. Morris Plains, NJ: Author.
ing cessation after acute myocardial infarction: the effects of exercise 103. Rose, J. E., Levin, E. D., Behm, F. M., et al. (1990). Transdermal nicotine
7
7
training. Addictive Behaviors, 13, 331–335. facilitates smoking cessation. Clinical Pharmacology and Therapeutics, 47,
75. Shiffman, S. (1986). A cluster-analytic classification of smoking relapse 323–330.
episodes. Addictive Behaviors, 11, 295–307.